Form D Summary: Altathera Pharmaceuticals $1.00 million Financing. Stephen OSullivan Published Nov 3 Form D

Pharmaceuticals Altathera Pharmaceuticals, Llc - Stephen OSullivan

Altathera Pharmaceuticals Financing

Altathera Pharmaceuticals, Llc, Limited Liability Company just had published form D because of $1.00 million equity financing. This is a new filing. Altathera Pharmaceuticals was able to sell $225,000 so far. That is 22.50% of the financing offer. The total offering amount was $1.00 million. The offering form was filed on 2016-11-03. The reason for the financing was: Commission listed subject to full placement of offering.. The fundraising still has about $775,000 more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Altathera Pharmaceuticals is based in Illinois. The company’s business is Pharmaceuticals. The D form was submitted by Stephen OSullivan General Counsel and Chief Compliance Officer. The company was incorporated more than five years ago. The filler’s address is: 200 South Wacker Drive – Suite 3100, Chicago, Il, Illinois, 60606. Brandon Kashfian is the related person in the form and it has address: 200 South Wacker Drive, Suite 3100, Chicago, Il, Illinois, 60606. Link to Altathera Pharmaceuticals Filing: 000160412116000004.

Analysis of Altathera Pharmaceuticals Offering

On average, firms in the Pharmaceuticals sector, sell 60.90% of the total offering size. Altathera Pharmaceuticals sold 22.50% of the offering. The financing is still open. The average financing size for companies in the Pharmaceuticals industry is $556,000. The offering was 59.53% smaller than the average of $556,000. Of course this should not be seen as negative. Firms get financed for a variety of reasons and needs. The minimum investment for this fundraising was set at $0. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Altathera Pharmaceuticals Also

The Form D signed by Stephen OSullivan might help Altathera Pharmaceuticals, Llc’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment